1. Home
  2. HL vs TWST Comparison

HL vs TWST Comparison

Compare HL & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hecla Mining Company

HL

Hecla Mining Company

HOLD

Current Price

$15.26

Market Cap

11.3B

ML Signal

HOLD

Logo Twist Bioscience Corporation

TWST

Twist Bioscience Corporation

SELL

Current Price

$133.20

Market Cap

9.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
HL
TWST
Founded
1891
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3B
9.2B
IPO Year
2002
2018

Fundamental Metrics

Financial Performance
Metric
HL
TWST
Price
$15.26
$133.20
Analyst Decision
Buy
Buy
Analyst Count
10
13
Target Price
$22.78
★ $163.67
AVG Volume (30 Days)
★ 34.2M
2.8M
Earning Date
11-04-2026
11-13-2026
Dividend Yield
★ 0.10%
N/A
EPS Growth
★ 716.67
63.89
EPS
★ 0.15
N/A
Revenue
★ $645,957,000.00
$376,572,000.00
Revenue This Year
N/A
$21.17
Revenue Next Year
$29.59
$20.24
P/E Ratio
$103.57
★ N/A
Revenue Growth
★ 45.63
20.32
52 Week Low
$11.81
$23.30
52 Week High
$34.17
$219.71

Technical Indicators

Market Signals
Indicator
HL
TWST
Relative Strength Index (RSI) 33.87 38.61
Support Level $13.98 $117.74
Resistance Level $16.43 $155.44
Average True Range (ATR) 0.58 15.61
MACD -0.19 -6.30
Stochastic Oscillator 22.04 2.65

Price Performance

Historical Comparison
HL
TWST

About HL Hecla Mining Company

Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Share on Social Networks: